Dialysis world news


ERA/EDTA Congress News. Day 1. PDF Print
From Amsterdam.

...

 
Baxter presents VIVIA HD machine data at ERA/EDTA PDF Print
Bloomberg: Baxter International Inc. (NYSE:BAX) today announced the presentation of clinical data supporting the safety and efficacy of the VIVIA haemodialysis (HD) system. Results from two studies conducted in a clinical setting showed acceptable clearance of uremic toxins and an overall safety profile similar to that associated with conventional HD devices. The VIVIA system, designed to deliver High Dose HD in the home, completed the CE marking process (market approval) in Europe, December 2013. The VIVIA haemodialysis system, which completed the CE marking process in Europe in December 2013, was designed to deliver High Dose HD therapy in the home.

...

 
Samsung plans to open source digital health gadgets. PDF Print
MDDI: This week Samsung put out a call to innovative startups to join it in creating the next-generation of wearable platforms for digital health. The company has announced a $50 million investment fund it is calling the Samsung Digital Health Challenge and wants to develop advanced data collection sensors and algorithms that will create actionable analysis of health tracking data. And it wants to use open hardware and software to do it. Essentially Samsung is creating a digital health playground and it wants startups, entrepreneurs, and research organizations to get into the sandbox.

...

 
Nitrosomonas - an alternative approach to S. aureus decolonization? PDF Print
Nitrosomonas eutropha, an ammonia-oxidizing bacteria (AOB) that is most commonly found in dirt and untreated water. AOBiome scientists hypothesize that it once lived happily on us too — before we started washing it away with soap and shampoo — acting as a built-in cleanser, deodorant, anti-inflammatory and immune booster by feeding on the ammonia in our sweat and converting it into nitrite and nitric oxide.

...

 
ZS Pharma presenting data on it's GI potassium sorbent in patients taking RAAS inhibitors at ASH PDF Print
ZS Pharma: The ZS003 sub-group analysis, which was pre-specified, specifically looked at patients taking renin-angiotensin-aldosterone system inhibitor (RAASi) drug therapies, including angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs) and aldosterone blockers. Results demonstrated that both the 5g and 10g doses of ZS-9, administered once daily, controlled potassium at normal levels in these hyperkalemic patients.

...

 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 5 of 2408
Share |
Copyright © 2014 Global Dialysis. All Rights Reserved.